Company ProfilePremium

ImExHS Limited

Company Profile Analysis

Ticker: IME.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
ImExHS Limited - Company showcase

Year Founded & Workforce

2012

300 Employees

ImExHS Limited logo

ImExHS Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ImExHS Limited Overview

IMEXHS is a Latin America-focused, cloud-native medical imaging software and radiology services company listed in Australia. Founded by Colombian radiologists and engineers in 2012, it sells a vendor-neutral, zero-footprint suite: PACS, RIS, cardiology information system, anatomical pathology LIS and universal viewer. These are now consolidated on the Aquila+ platform, which embeds proprietary "agentic" AI workflow agents. The company also owns RIMAB SAS, a Colombian outsourced radiology and teleradiology provider that runs entirely on IMEXHS software. RIMAB generates about two-thirds of group revenue and acts as a live laboratory and data source for the AI agents. With A$29.0m FY25 revenue, A$36.8m ARR at June 2026 and about 97% recurring revenue, IMEXHS is a sub-scale but recently EBITDA-positive challenger to global PACS incumbents. It competes on cost, cloud delivery, Spanish-language local support and partner-led distribution across 18 countries. Its principal exposures are Colombian healthcare-payer liquidity and customer concentration.


What the company does

IMEXHS operates two complementary business units, which are also its two reportable segments.

  1. IMEXHS Software. This unit develops and sells cloud-based medical imaging software on a subscription (SaaS) basis. The product set covers:

    • Picture Archiving and Communications System (PACS)

    • Radiology Information System (RIS)

    • Cardiology Information System (CIS)

    • Anatomical Pathology Laboratory Information System (APLIS)

    • a universal diagnostic viewer, patient portal and results-distribution tools The company describes its solutions as completely cloud-based, vendor neutral and zero footprint, with no need for locally installed software (company boilerplate, 1H FY26 announcement). Since 2025 the flagship is Aquila+, the next-generation radiology platform. Aquila v3 remains in use and is often deployed alongside Aquila+ (2026 AGM address). By 30 June 2026 the company had 569 IMEXHS Enterprise and IMEXHS Cloud installations worldwide (1H FY26 results).

  2. Radiology Services (RIMAB SAS). This unit provides outsourced radiology, teleradiology and outpatient-clinic imaging services, mainly in Colombia. It serves hospitals, insurers (EPS) and clinic networks. RIMAB was acquired in October 2021. It operates exclusively on IMEXHS software, and AI agents built by the software business run inside RIMAB's own operation (1H FY26 Results Presentation).

Business model and revenue model

Revenue typeDescriptionShare of revenue
Subscription SaaS (software)Monthly recurring fees for IMEXHS Cloud (standardised, multi-tenant) and IMEXHS Enterprise (larger, customised deployments). Often priced per study or volume band.Software was about 34% of FY25 revenue (derived: A$10.0m of A$29.0m) and 30% of 1H FY26 revenue (A$4.8m of A$16.0m)
Recurring services (radiology)Contracted reading and reporting, on-site radiology department management and teleradiology. Billed monthly, frequently per-study volume.About 66% of FY25 revenue (A$19.0m) and 70% of 1H FY26 revenue (A$11.2m)
One-off / implementationImplementation fees (for example a US$50,000 one-time fee on the Zacatecas, Mexico tender), hardware and occasional perpetual or one-off salesSmall. Recurring revenue was about 97% of total in FY25 (AGM 2026 commentary).
Licensing via partnersPartner Programme distributors resell IMEXHS Cloud/Aquila+Included in software. Partners delivered 75% of software new ARR in 1H FY26.

The company's key operating metric is Annualised Recurring Revenue (ARR), defined as monthly recurring contract revenue multiplied by twelve. A further component, "contracted but not yet billing" ARR, is reported separately. This was A$2.3m for software at 30 June 2026 (1H FY26 results).

Value chain position

IMEXHS sits at the clinical-IT application layer of the diagnostic imaging value chain:

Upstream: modality OEMs such as CT, MR and X-ray makers. Neusoft Medical is a partner (December 2021).

Downstream: radiologists and referring clinicians.

Third-party AI: algorithms are integrated on top. Gleamer's ChestView and Fracture Detection were embedded in the 2026 Mexico tender.

Through RIMAB, IMEXHS also integrates forward into the clinical service itself. That makes it unusual among PACS vendors: it is both a software vendor and a radiology service operator.

Customer types and end markets

Customer typeExamples disclosed
Public hospitals / health systemsColombian National Police Central Hospital (contract December 2021, renewed Q4 FY24); 20 public hospitals and clinics in Zacatecas, Mexico (May 2026 tender via distributor GOBA); Subred Integrada de Servicio de Salud Sur ESE, Bogotá
Private hospital groups / clinicsHospital General de Medellín; Clínica del Occidente; Hospital Moncaleano; Hospital La Misericordia; Neurológico de México; CESAC IPS (Cartagena); Clínica El Carmelo (El Salvador)
Health insurers / payers (EPS) and integrated providersColsubsidio; Famisanar (A$1.1m ARR, March 2023); Sanitas and Colsanitas (two radiology contracts commencing Q3 FY26, about A$2.0m combined ARR)
Diagnostic imaging centres and outpatient networksDiodiagnóstico (extension bringing ARR to A$490,000); DPI (Peru); Pulso Salud (Peru, A$163,000 NARR); Imágenes del Centro (Venezuela, five centres); Someditec
Channel partners47 partners across 13 LATAM countries (1H FY26), mainly Colombia (15), Mexico (9) and Ecuador (6)

End markets are diagnostic imaging IT and radiology services in Latin America, mainly Colombia, Mexico, Peru, Ecuador and Central America. There is a residual presence in Spain, the US and Australia; boilerplate states 18 countries "including Colombia, the US and Australia".

Company's own description versus independent characterisation

Company description (paraphrased from the 2026 AGM and 1H FY26 materials): IMEXHS runs two complementary businesses with a single mission of making specialist medical imaging diagnosis more efficient and accessible. The software division builds cloud-native radiology software centred on Aquila+, now an AI-native, agentic platform. The radiology services division (RIMAB) places radiologists and reporting capacity into hospitals and runs on that software.

Independent characterisation: Economically, IMEXHS is a Colombian radiology services business (about 66–70% of revenue, thin but improving margins) attached to a small, higher-margin regional SaaS business. The software business has about A$11.8m ARR and roughly a 30% segment EBITDA margin in FY25 (AGM 2026 summary).

The investment case rests on the software unit scaling through partners and Aquila+, while RIMAB funds itself and supplies proprietary workflow data. The main structural weaknesses are:

  • exposure to Colombian payer liquidity

  • a single customer at about 33% of external FY25 revenue

  • low absolute scale against global incumbents

  • a history of equity dilution

Strategy

Stated strategy themes (latest Annual Report, AGM and 1H FY26 presentation)

  1. AI-first product strategy. Embed proprietary AI agents progressively across the radiology workflow. Management's argument is that owning the full workflow, rather than a single point within it, creates durable value (CEO, 1H FY26).

  2. Scale software with Aquila+ as the preferred radiology platform across LATAM. All new contracts are to deploy on Aquila+.

  3. Partner-led distribution. The Partner Programme grew from 25 partners in 15 countries (2025) to 47 partners in 13 LATAM countries (1H FY26), contributing 75% of software NARR in 1H FY26.

  4. Radiology services: profitability over growth. Grow opportunistically where margins are healthy and counterparties reliable. Exit sub-scale or late-paying contracts. Focus is shifting to collections and working capital.

  5. Customer success. Retention, Aquila+ migration, satisfaction, upsell and cross-sell, and AI adoption (1H FY26 presentation).

  6. Financial discipline. Tight cash management through 2026, debt reduction (to A$0.25m) and hard-currency pricing.

  7. Commercial transformation. Tighter qualification, disciplined pipeline management and a shift toward higher-quality opportunities. Management acknowledged in 1H FY26 that this was incomplete.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDetail / target
FY24–FY25"New Value Proposition" software development programme leading to Aquila+Initial installs at 8 sites; on time and on budget for a second year (AGM 2026)
2024–2025Radiology Profit Improvement ProgramPricing and productivity; RIMAB EBITDA margin improved from about 0% to 7% (FY25)
Apr 2025Equity raiseA$2.5m placement (including A$1.0m from directors) plus SPP; total A$2.6m
2,025Partner Programme expansionFrom 25 to 47 partners; SAGRILAFT anti-money-laundering and counter-terrorist-financing review of all partners completed in 1H FY26 with no exceptions
28 Apr 2026Launch of the agentic AI platform for radiologyFive proprietary agents, rising to eight by August 2026
May 2026Gleamer algorithm integrationChestView and Fracture Detection in the Zacatecas deployment
2,026Leadership refreshNew CTO, Sales Director, COO, CFO and Sales Manager
2,026Platform engineeringSuperadmin multi-tenant module; DICOM gateway scaling; lower storage, compute and engineering cost design
ESG / sustainabilityNo quantified commitments disclosed—

Medium-term targets and guidance

ItemGuidanceSource
FY26 revenueA$31.4m to A$33.7m (+8% to +16%)1H FY26 results, 28 Aug 2026
FY26 underlying EBITDAA$2.4m to A$2.7m (+48% to +66%)1H FY26 results
FY26 cashCash positive for the full year (AGM, May 2026; quarterly reports)AGM 2026
FY26 softwareGrow software revenue faster than in FY25AGM 2026
PhasingMore growth in revenue, earnings and cash in 2H FY26AGM 2026
Medium-term targets (beyond FY26)——

Products & Services

Software segment

Product / platformDescription and capabilitiesTarget customerLaunch / latest versionPricing model
Aquila+ (flagship)Next-generation, cloud-native RIS-PACS radiology platform with embedded proprietary AI agents. Commercially live from Q1 FY25 (8 initial sites). 2026 work advanced the diagnostic viewer and scheduling modules, added a superadmin module for centralised multi-tenant operations, and strengthened DICOM gateway scaling for high-volume, multi-node environments. The company expects all new software contracts to deploy on Aquila+.Hospitals, imaging networks, public health systemsInitial installs FY24; commercial launch Q1 FY25; agentic version April 2026Subscription (per study or volume tier, monthly). Exact price list not publicly disclosed.
Aquila+ Agentic AI Platform: proprietary AI agentsLaunched 28 April 2026 with five agents covering scheduling, study prioritisation (triaging urgent and critical studies), auto-distribution of worklists, non-attendance alerts and AI-assisted report generation. By August 2026 eight agents were developed. The additional three extend into image visualisation and patient-survey workflows, plus a report-enhancement agent that incorporates patient and study context into dictated reports. Agents are trained on proprietary workflow data from RIMAB.Aquila+ customers and RIMAB internallyApril 2026 (five agents); August 2026 (eight agents)Bundled or add-on. Not publicly disclosed.
Aquila v3Prior-generation Aquila platform, still in use and often deployed alongside Aquila+ as features migrateInstalled basev3 (pre-2025)Subscription
IMEXHS Enterprise (formerly Aquila Enterprise / Aquila Custom)Customised, larger-scale RIS/PACS deployments that can include hardware and reporting services. Software ARR A$5.7m at end FY22.Large hospitals, public sector, hospital groupsOngoingSubscription or custom contract
IMEXHS Cloud (formerly Aquila in the Cloud, AiC)Standardised, multi-tenant cloud PACS/RIS for small and medium imaging centres, sold heavily through partners. 169 active contracts and A$3.5m ARR at end FY22. Tiered as IMEXHS Cloud SME and IMEXHS Cloud Enterprise.SMEs: clinics, imaging centres, dental groupsAiC May 2020; IMEXHS Cloud Nov 2021Monthly subscription
HIRUKO™Original multi-tenant imaging platform underpinning AiC; also deployed in dental and teleradiology use cases (for example Radiofam at seven sites; Hunter Dental Group)Legacy and installed basePre-2018Subscription
IMEXHS Universal Viewer (radiology and pathology)Zero-footprint diagnostic viewer for DICOM radiology and digital pathology imagesAll customersUpgrades through 2025–2026Included or subscription
RISScheduling, worklists, reporting and billing workflowImaging departmentsOngoing; folded into Aquila+Subscription
PACSImage archiving and communication; vendor-neutral archive capabilitiesImaging departmentsOngoingSubscription or storage-based
CISCardiology Information SystemCardiology departments—Subscription
APLISAnatomical Pathology Laboratory Information SystemPathology laboratories—Subscription
Patient Portal / Results Distribution PortalPatient and referrer access to images and reportsProviders and patientsEnhancements Q1 FY25Included
IMEXHS BoxOn-premises gateway or edge appliance complementing IMEXHS Cloud, enabling extensions and add-ons from the cloudSites needing local connectivityAnnounced Dec 2021—
IMEXHS-U (IMEXHS Classroom)Online training, installation and support academy for customers and partners outside ColombiaPartners and customers2020–2021—
Integrated third-party AI (Gleamer ChestView, Gleamer Fracture Detection)Diagnostic AI algorithms embedded with Aquila+ in the Zacatecas, Mexico deploymentPublic hospitals (Mexico)May 2026Bundled in tender

Radiology Services segment

ServiceDescriptionTarget customerNotes
Outsourced radiology department managementRIMAB runs radiology departments inside client hospitals, including radiologists, technologists and reportingHospital groups, EPS insurers (for example Colsubsidio, National Police Hospital)Revenue-share structures with IMEXHS existed pre-acquisition
Teleradiology reading and reportingRemote reporting for hospitals in Colombia and historically SpainHospitals and clinicsUses Aquila and Aquila+ with AI agents
Outpatient imaging clinicsDiagnostic imaging services delivered through clinic sitesPatients via insurersDisclosed in the 1H FY26 presentation ("outpatient clinics")
AI-enabled operationsCall-centre orchestration, scheduling and triage agents deployed inside RIMABInternalAI orchestrates call-centre workflow (1H FY25 results)

Financial Narrative

All figures are A$ M, year to 31 December, unless stated. Sources: annual results announcements FY21–FY25, investor presentations, Appendix 4E, and InvestSMART/Morningstar aggregator data where noted. "Underlying EBITDA" is the company's non-IFRS measure excluding FX, share-based payments, impairment and one-off items.

Income statement

Notes:

  • FY21: revenue, EBITDA (-3.0) and underlying EBITDA (-1.4) are from the FY21 results. Consolidated loss before tax was A$4.6m (FY20: A$3.5m).

  • FY22: revenue A$17.1m, EBITDA loss A$0.8m and underlying EBITDA loss A$0.1m are from the FY22 results.

  • FY23: revenue A$19,669k; EBITDA loss A$1,291k after a A$1,277k impairment; underlying EBITDA A$448k (FY23 Investor Presentation). The FY24 results later describe the FY23 comparative underlying EBITDA as A$0.2m, which is a restatement or redefinition. Net profit after abnormals of -A$4.2m is from InvestSMART/Morningstar.

  • FY23 EPS: InvestSMART shows -7.0 cents. Simply Wall St shows -A$0.11 for FY23. The difference is unresolved.

  • FY24: revenue A$26.5m (statutory A$26.4m in the Appendix 4E); net loss A$2.6m, down 41%; EPS -5.8c (Simply Wall St); EBITDA about A$0.02m (InvestSMART).

  • FY25: revenue A$29.0m; underlying EBITDA A$1.6m; after-tax loss A$2.9m (Smallcaps summary of FY25 results). EBITDA A$1.28m and EPS -2.2c (pre-abnormals) are from InvestSMART. The FY25 net loss includes the 1H FY25 A$1.7m Radiology CGU impairment. InvestSMART shows "net profit before abnormals" of -A$1.1m.

Gross profit and operating income (EBIT): not reported as headline metrics in sources reviewed. Simply Wall St reported FY24 cost of sales of A$15.5m (59% of revenue), which implies FY24 gross profit of about A$11.0m (41% gross margin, derived).

Diluted EPS: equal to basic given losses.

Margins and growth

Margins are derived from the table above. Net margins are as published by InvestSMART/Morningstar. FY25 net margin per InvestSMART is -3.9%, which uses the pre-abnormal loss. Using the after-tax loss of A$2.9m gives about -10%.

Revenue CAGR FY21–FY25: (29.0 / 13.4)^(1/4) − 1 ≈ 21.3% per year (derived). This is flattered by the RIMAB acquisition in Q4 FY21. On a like-for-like basis, FY22 growth excluding RIMAB was 7% (Q4 FY22 4C).

Balance sheet

Sources: FY21 Investor Presentation (cash A$4.2m, net assets A$16,653k); FY23 net assets A$15,726k (1H FY24 results comparative); FY24 net assets A$14.5m and cash A$2.1m (FY24 results); FY25 cash A$3.3m and debt A$0.53m (FY25 results; 1H FY26 results). Current assets and net gearing are from InvestSMART/Morningstar; negative gearing indicates net cash.

Additional balance-sheet datapoints:

  • 30 June 2023: cash A$2.0m, net assets A$16.7m.

  • 30 June 2024: net assets A$15.1m.

  • 30 June 2025: cash A$2.5m, debt A$1.3m (1H FY25 call).

  • 30 June 2026: cash A$2.0m, debt A$0.25m.

  • Net tangible assets per share fell from 16.77c (FY23) to 13.84c (FY24) (Preliminary Final Report FY24).

Goodwill and intangibles: goodwill arose on the RIMAB acquisition. It was impaired by A$1.3m (30 June 2023) and a further A$1.7m charge was taken against the Radiology CGU (1H FY25). Capitalised software development is a recurring investing outflow (A$0.6m in 1H FY26).

Net debt (derived): FY25: 0.53 − 3.3 = −A$2.8m (net cash). 30 June 2026: 0.25 − 2.0 = −A$1.75m (net cash).

Cash flow

Sources: FY21 Investor Presentation (OCF -A$2,968k; investing -A$3,386k, including RIMAB acquisition cash; financing -A$162k). FY23–FY25 are from InvestSMART/Morningstar and rounded. FY22 included a A$4.0m underwritten raise. FY25 included the A$2.5–2.6m placement and SPP.

Ratios

ROE is derived from the net loss and net assets above. Net interest cover is from InvestSMART. FY25 net debt to EBITDA is derived (−2.8 / 1.6), indicating net cash. ROA and ROIC are not meaningful given losses and are not computed. 1H FY26 receipts from customers were A$12.6m against revenue of A$16.0m, a cash-to-revenue ratio of about 79% (derived from 1H FY26 results). This illustrates elongated receivables.

Commentary on trends, inflections and drivers

Revenue. The FY21–FY22 step-up was acquisition-driven. RIMAB contributed A$1.2m in Q4 FY21 and a full year in FY22. FY22 like-for-like growth was only 7%. FY22 revenue of A$17.1m came in at the low end of guidance of A$17.0–19.0m, after the company had originally guided A$19.5–22.0m at the May 2022 AGM. That shortfall coincided with the voluntary exit of a slow-paying radiology customer on 1 July 2022.

FY23 growth of 15% was second-half weighted (2H revenue +42% versus pcp) as Famisanar and other contracts started billing. FY24 was the strongest growth year (+34%, radiology +45%), driven by repriced renewals (Colsubsidio, National Police) and new contracts.

FY25 growth slowed to 10%. Management deliberately prioritised margin and cash in radiology: it exited sub-scale or persistently late-paying contracts and accepted that these actions constrained radiology growth in 2025 (Q3 FY25 call; 1H FY25 results). FY26 guidance implies an 8–16% recovery.

Profitability inflection. Underlying EBITDA moved from a A$1.4m loss (FY21) to a A$1.6m profit (FY25), then to A$1.3m in 1H FY26 alone. FY26 guidance is A$2.4–2.7m. The drivers were:

  • RIMAB repricing, cost reduction and AI automation. RIMAB moved from near break-even to a 7% margin in FY25, then earned A$1.1m underlying EBITDA in 1H FY26 on A$11.2m revenue (about 10%, derived).

  • Corporate cost reduction. Corporate costs fell from about A$1.3m in 1H FY25 to A$0.6m in 1H FY26.

  • Directors taking fees in shares from 1 April 2022 (2022 Annual Report).

Software EBITDA has declined at the half-year level, from A$1.9m (1H FY24) to A$1.3m (1H FY25) to A$0.8m (1H FY26), even as software ARR rose. This reflects investment in Aquila+, AI agents and sales capacity, and is a key monitorable.

Statutory losses. Statutory net losses persist despite positive underlying EBITDA. The causes are recurring goodwill impairments (A$1.3m FY23; A$1.7m 1H FY25), depreciation and amortisation of capitalised software, FX losses on COP-denominated operations, share-based payments and finance costs. 1H FY26 was the first reported period with a statutory profit after tax (A$66,200, versus a A$3.0m loss in 1H FY25).

FX. Revenue is mostly generated in Colombian pesos and translated to A$. Management has shifted software pricing into hard currencies. The share of software revenue priced in USD, AUD or EUR rose from 31% (FY22) to 45% (FY23), 59% (FY24) and 69% (Q2 FY26); 73% of software ARR was in hard currencies at Q2 FY26. This reduces translation risk in the higher-margin unit.

Cash and working capital. This is the persistent weakness. FY24 revenue growth "consumed significant working capital" (FY24 results). 1H FY26 receipts trailed revenue because of Colombian healthcare-sector liquidity stress. That stress stems from delayed government payments to health insurers, and the largest customer delayed its March 2026 payment to April (1H FY26 results). The company has repeatedly relied on small equity raises: A$4.0m (2022) and A$2.5–2.6m (2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / services

Software (IMEXHS Software)

IMEXHS Enterprise, IMEXHS Cloud, Aquila+/Aquila v3, AI agents, Partner Programme sales

PACS, RIS, CIS, APLIS, Universal Viewer, Patient/Results Portal, IMEXHS Box, AI agents

Radiology Services (RIMAB plus other services)

RIMAB SAS and other IMEXHS radiology service arrangements, including joint operations

Outsourced radiology departments, teleradiology reading and reporting, outpatient imaging clinics

Corporate (unallocated)

Listed-company costs and group overheads

—

Revenue by Segment

SegmentFY22FY23FY24FY25

Software revenue (AUD Mn)

6.47.68.910.0

Radiology Services revenue (AUD Mn)

10.712.117.619.0

Total revenue (AUD Mn)

17.119.726.529.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Segment metric1H FY241H FY251H FY26

Software revenue (AUD Mn)

4.94.74.8

Radiology revenue (AUD Mn)

8.99.011.2

Software underlying EBITDA (AUD Mn)

1.91.30.8

Radiology underlying EBITDA (AUD Mn)

-0.10.31.1

Corporate underlying EBITDA (AUD Mn)

-1.5-1.3-0.6

Group underlying EBITDA (AUD Mn)

0.30.31.3

Segment Margins & Growth (%)

MetricFY23FY24FY25

Software % of group revenue

393434

Radiology % of group revenue

616666

Software YoY revenue growth (%)

191712

Radiology YoY revenue growth (%)

12458

Software underlying EBITDA margin (%)

——30

Radiology underlying EBITDA margin (%)

—

about 0

7

“—” = not publicly disclosed.

Revenue by Segment (FY21–FY25)

Segment ARRFY21FY22FY23FY24FY25

Software ARR (AUD Mn)

7.19.210.59.911.8

Radiology ARR (AUD Mn)

13.310.514.520.123.0

Total ARR (AUD Mn)

20.419.725.030.034.8

Group Entities

EntityJurisdictionRole

IMEXHS Limited

Australia

ASX-listed parent

Imaging Experts and Healthcare Services Pty Ltd

Australia

Intermediate holding company acquired in the 2018 reverse takeover

IMEXHS Colombia (local operating company)

Colombia

Software development, sales and support.

RIMAB SAS

Colombia

Radiology services (acquired 5 Oct 2021)

Joint operation, National Police Hospital contract (97% interest)

Colombia

Radiology contract vehicle formed December 2024

Other subsidiaries (Spain, US, Mexico and others)

Various

—

Income Statement and Margin Analysis (%)

MetricFY21FY22FY23FY24FY25

Revenue (AUD Mn)

13.417.119.726.529.0

Revenue growth YoY (%)

2328153410

Recurring revenue (AUD Mn)

12.2————

ARR at year end (AUD Mn)

20.419.725.030.034.8

Reported EBITDA (AUD Mn)

-3.0-0.8-1.30.01.3

Underlying EBITDA (AUD Mn)

-1.4-0.10.40.51.6

Net profit after tax (AUD Mn)

——-4.2-2.6-2.9

Basic EPS (A$ cents)

——-7.0-5.8-2.2

Dividends per share (AUD)

00000

“—” = not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%) and Financial Ratios (x)

MetricFY21FY22FY23FY24FY25

Underlying EBITDA margin (%)

-10.4-0.62.01.95.5

Reported EBITDA margin (%)

-22.4-4.7-6.60.14.4

Net margin (%)

——-14.8-9.9-3.9

ARR / revenue (x)

1.521.151.271.131.20

Balance Sheet and Margin Analysis (%)

MetricFY21FY23FY24FY25

Cash and equivalents (AUD Mn)

4.22.42.13.3

Total debt (AUD Mn)

———0.53

Net assets / equity (AUD Mn)

16.715.714.5—

Total current assets (AUD Mn)

—8.929.2613.44

Net gearing (%)

—-6.7-6.1-17.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY21FY22FY23FY24FY25

Operating cash flow (AUD Mn)

-3.0—2.6-0.60.6

Investing cash flow (AUD Mn)

-3.4—-2.0-1.0-1.0

Free cash flow, OCF plus investing (AUD Mn)

-6.4—0.6-1.6-0.4

Financing cash flow (AUD Mn)

-0.2——1.02.0

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY23FY24FY25

ROE (%), net loss / closing equity

-26.7-17.9—

Net interest cover (x, aggregator)

-8.18-4.88-2.68

Net debt / underlying EBITDA (x)

——-1.8

Revenue by Region and Revenue by Region (%)

Region (proxy)FY23FY24FY25

Colombia, radiology services (AUD Mn)

12.117.619.0

Software, all geographies (AUD Mn)

7.68.910.0

Software priced in hard currency, mainly ex-Colombia (% of software revenue)

455968

Date / Period Details

Date / periodPriceSource

Aug–Sep 2018 (post-RTO, pre-consolidation)

0.031–0.046 range (pre 50:1 consolidation)

ASX announcement, Nov 2018

2 Sep 2025

0.220

InvestSMART

26 Sep 2025

0.235

InvestSMART

23 Dec 2025

0.370

InvestSMART

27 Feb 2026

0.410

InvestSMART

30 Apr 2026

0.390

InvestSMART

25 May 2026

0.360

InvestSMART

29 Jul 2026

0.280

InvestSMART

28 Aug 2026

0.350

InvestSMART

1–4 Sep 2026

0.350–0.355

InvestSMART

Share Price & Returns

HorizonPerformanceNote

1 year

About +32% (TradingView, as of a 2026 date); about +51–61% from A$0.22–0.235 (Sep 2025) to A$0.355 (Sep 2026) (derived)

Strong recovery after the FY25 turnaround

Valuation Snapshot

MetricValueBasis

Market capitalisation

About A$18m

Midpoint of A$17–19m (InvestSMART, Jul–Sep 2026)

Net cash (30 Jun 2026)

About A$1.75m

Cash A$2.0m less debt A$0.25m

Enterprise value

About A$16m

Derived

EV / FY25 revenue (x)

0.56

16 / 29.0

EV / FY26 guided revenue, midpoint A$32.6m (x)

0.49

Derived

EV / FY25 underlying EBITDA (x)

10.2

16 / 1.6

EV / FY26 guided underlying EBITDA, midpoint A$2.55m (x)

6.3

Derived

EV / ARR, June 2026 (x)

0.44

16 / 36.8

P/B

About 1.2x (estimated)

—

Source Details

SourceViewNote

TradingView

Single estimate, price target A$0.35 (max and min both A$0.35)

Implies one covering analyst

TipRanks (2025)

"Buy" with A$1.15 target

Conflicts with TradingView. The A$1.15 figure may be stale or erroneous; treat with caution.

Simply Wall St

Revenue forecast about 18% per year over three years (as of FY24 results)

Aggregator forecast

Capital Markets

ItemStatus

Dividend history

None; IME has never paid a dividend

Dividend policy

No dividend policy; earnings retained for growth

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt

A$0.25m at 30 June 2026 (A$0.53m at 31 Dec 2025; A$1.3m at 30 June 2025). Lender, terms and maturity not publicly disclosed in sources reviewed. Likely short-term Colombian bank facilities.

Equity raises

2018 A$5.5m; Oct 2019 A$10m at A$0.04 (pre-consolidation); Oct 2020 A$8.3m at A$0.03 (pre-consolidation); Aug 2022 A$4.0m underwritten; Apr–May 2025 A$2.5m placement plus SPP at A$0.35

Balance Sheet

RaiseFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Equity raised (AUD Mn)

5.510.08.804.0002.6

Analyst Conclusions

Management guidance (28 August 2026)

  • FY26 revenue of A$31.4–33.7m (+8% to +16%)

  • FY26 underlying EBITDA of A$2.4–2.7m (+48% to +66%)

  • Cash positive for FY26 (AGM, May 2026)

  • Software revenue growth faster than FY25

  • 2H weighting of revenue, earnings and cash

Implied 2H FY26: revenue A$15.4–17.7m and underlying EBITDA A$1.1–1.4m (derived, since 1H was A$16.0m and A$1.3m). The lower end implies a softer second half than the first, which is notable given the stated H2 weighting.

Consensus

There is effectively no consensus: one or two estimates at most. Simply Wall St's aggregator forecast of about 18% annual revenue growth exceeds the upper end of FY26 guidance.

Bull case

  1. Contracted ARR step-up into 2H FY26 and FY27. A$2.3m of software ARR is contracted but not yet billing, Zacatecas reaches full run-rate from September 2026, and Sanitas and Colsanitas add about A$2.0m ARR from Q3 FY26. Together these could lift exit-FY26 ARR towards about A$40m (analyst estimate) against an enterprise value of about A$16m.

  2. Operating leverage is now visible. Underlying EBITDA in 1H FY26 (A$1.3m) nearly equalled the whole of FY25 (A$1.6m). Corporate costs halved. RIMAB's margin has risen to about 10%. Converting EBITDA to statutory profit (1H FY26 A$66,200) can re-rate the stock from a "perennial loss-maker" multiple.

  3. Differentiated AI positioning with real-world proof. Eight proprietary agents run in a live radiology operation (RIMAB) and a 20-site public deployment, combined with a partner channel that already generates 75% of NARR. This could make IMEXHS a strategic asset for an OEM or global PACS vendor seeking LATAM scale.

Bear case

  1. Cash and receivables fragility. Cash fell from A$3.3m to A$2.0m in 1H FY26 despite positive EBITDA. Receipts were 79% of revenue, and one customer is about 33% of revenue. Another Colombian payment shock could force a dilutive raise at a depressed valuation; placement capacity was approved at the 2026 AGM.

  2. Software growth is not yet proven repeatable. Software revenue was flat in 1H FY26 (A$4.8m versus A$4.7m). Software ARR was flat half-on-half (A$11.8m). Software segment EBITDA has declined for three consecutive halves. Management itself described smaller-deal conversion as inconsistent.

  3. Structural statutory unprofitability and quality-of-earnings concerns. Underlying EBITDA excludes FX, share-based payments, impairments and credit losses. Two goodwill impairments in three years and repeated restatements of comparative underlying EBITDA and ARR (FY23 underlying EBITDA 0.4 versus 0.2; software ARR 10.5 versus 9.1) reduce confidence in adjusted metrics.

Key catalysts and monitorables (next 12 months)

Timing (expected)Catalyst / monitorable
Late Oct 2026Q3 FY26 4C: confirm billing commencement of A$1.2m contracted software ARR; Sanitas and Colsanitas go-live; Zacatecas full run-rate; receipts versus revenue
Late Jan 2027Q4 FY26 4C: full-year cash-positive delivery
Late Feb 2027FY26 results versus A$31.4–33.7m / A$2.4–2.7m guidance; statutory NPAT; any further impairment; FY27 guidance
OngoingSoftware NARR cadence (target: steady mid-market flow beyond tenders); partner count and productivity
OngoingConcentration: largest customer payment behaviour; Colombian payer reform under the new administration
OngoingSoftware segment EBITDA trend (stabilisation from A$0.8m per half)
OngoingCapital management: any use of the 7.1A placement capacity
OngoingNew CFO's first reporting cycle; audit opinion on FY26 accounts
OngoingAdditional AI agent commercialisation and any regulatory clearances

Analyst verdict

IMEXHS has completed the hardest part of a micro-cap turnaround. A loss-making, acquisition-inflated imaging IT business in FY21 (underlying EBITDA −A$1.4m) has become an EBITDA-positive, about 97% recurring-revenue operator. It guides to A$2.4–2.7m underlying EBITDA in FY26 and reported its first statutory profit half in 1H FY26. The radiology arm, RIMAB, once the source of goodwill write-downs, now earns about a 10% margin and is a positive cash contributor. It also gives the company something few small PACS vendors have: a live clinical operation in which to build and prove AI workflow agents. The Zacatecas tender shows that this combination can win public-sector business against larger rivals.

At about A$16m enterprise value, the market capitalises IMEXHS at roughly 0.4–0.5x ARR and about 6x FY26 guided underlying EBITDA. That is a deep discount to any listed imaging software peer. It reflects real risks rather than neglect alone:

  • dependence on Colombian payer liquidity

  • one customer at about a third of revenue

  • a cash balance of only A$2.0m

  • a software unit whose revenue and segment EBITDA have not yet re-accelerated despite the Aquila+ investment cycle

Adjusted metrics also require scrutiny given repeated impairments and restated comparatives.

Our synthesis is that IMEXHS is a high-risk, asymmetric special situation. The next two to three quarters are decisive. Confirmation that contracted ARR converts to billing and to cash would validate the re-rating case. The tests are Zacatecas at full run-rate, Sanitas and Colsanitas live, and A$1.2m of not-yet-billing software ARR starting by end Q3 FY26, with receipts converging on revenue. A further collection shock or a dilutive raise would reset the thesis. Investors should weight cash conversion and software NARR consistency above headline underlying EBITDA when judging progress.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundIndependence

Douglas (Doug) Flynn

Non-Executive Chairman

March 2020 (invested A$0.5m on joining)

About 30 years in media and ICT. Former CEO of Davies Brothers Ltd (acquired by News Corporation, 1989); Managing Director of News International plc (from 1995); leadership roles at Aegis Group and Rentokil Initial. Long-serving Chair of NEXTDC (ASX: NXT, director since Sep 2013). Senior Fellow of FINSIA; member of AICD.

—

Dr Germán Arango

Co-Founder, CEO and Managing Director

Founder 2012; MD/CEO from Aug 2018

Radiologist with more than 19 years' practice in Colombia; professor of neuroradiology at several Colombian universities. Co-founder and former majority owner of RIMAB.

Executive, not independent

Damian Banks

Non-Executive Director

22 May 2020

Former CEO and MD of Konekt Ltd (2011–2019); earlier Westpac leadership roles. Chairman of Kip McGrath Education Centres; NED of Boom Logistics; former Chair of Vection Technologies; former director of ICSGlobal and RPM Automotive. University of Tasmania graduate.

Independent NED

Carlos Palacio

Non-Executive Director

28 Aug 2018 (formerly Non-Executive Chairman, 2018–2020)

——

Douglas Lingard

Non-Executive Director

6 Jan 2021

——

Executive Leadership Team

NameTitleTenureNotes

Dr Germán Arango

CEO and Co-Founder

2012–present

See above

Fabio Carrillo

CFO

From 1 Aug 2026

Chartered Accountant; Bachelor of Commerce (Professional Accounting), Macquarie University; 20 years in public practice in tax and business advisory. Supported by Crofts CA and a strengthened Colombian finance team.

Reena Minhas

CFO and Company Secretary (former)

1 Oct 2020 to 31 Jul 2026

Resigned; orderly handover completed

Kamille Dietrich (Automic Group)

Company Secretary

From 27 Jul 2026

Outsourced company secretarial service

Daniel Laverde

COO

From April 2026

Succeeded Orlando Joven

Orlando Joven

COO (former)

Departed 1H FY26

—

Mario Huyo

Sales Manager

Appointed 1H FY26

—

New CTO and Sales Director

—

Appointed by May 2026

—

Dr Jorge Marín

Co-Founder; Chief Medical Officer / Medical Director

From 2018

—

Andrés Vanegas

Chief Sales Officer (2018–2020 references)

——

Major Shareholders

HolderStakeSource / date

Unnamed substantial holder

Decreased from 16.54% to 15.28% (on-market trading and dilution)

TipRanks summary of Form 604; date c.

Douglas Flynn (direct and indirect)

About 3.77m direct and 0.63m indirect shares (about 8% of an estimated 54m shares, derived)

MarketIndex directors' holdings, 1 June 2026. Sold 2.18m shares off-market at A$0.41 on 5 May 2026.

Other directors

Small; Banks participated in the April 2025 director placement (328,572 shares at A$0.35)

Appendix 3Y

Competitive Landscape

Competitors by Segment

SegmentCompetitorHQPositioning versus IMEXHS

Enterprise imaging / PACS

Philips (Philips Enterprise Imaging; legacy Carestream HCIS)

Netherlands

Global incumbent; strong in large LATAM hospitals; high price

Enterprise imaging / PACS

GE HealthCare (Centricity / True PACS)

USA

Bundles with modalities; strong public-tender presence

Enterprise imaging / PACS

Siemens Healthineers (syngo.via / syngo.plaza / teamplay)

Germany

Modality-linked; large hospitals

Enterprise imaging / PACS

Fujifilm (Synapse)

Japan

Leading PACS share globally

Enterprise imaging / PACS

Agfa HealthCare (Enterprise Imaging)

Belgium

Historic LATAM installed base

Enterprise imaging / PACS

Sectra

Sweden

Premium enterprise imaging; limited LATAM presence

Enterprise imaging / PACS

Intelerad

Canada

Cloud PACS for imaging centres

Enterprise imaging / PACS

Pro Medicus (Visage 7)

Australia

ASX-listed premium enterprise viewer; US academic focus; not a LATAM rival but the key ASX valuation comparator

Cloud PACS / SME

Regional cloud PACS vendors and open-source PACS deployments

LATAM

—

AI radiology

Gleamer, Lunit, Aidoc, Annalise.ai

Various

Point-solution AI. Gleamer is a partner. Aidoc's orchestration platform overlaps conceptually with IMEXHS's agentic positioning.

Radiology services (Colombia)

Hospital-owned radiology departments; national imaging chains; other teleradiology providers

Colombia

Fragmented; insurers often integrate imaging internally.

Competitor Detail

MetricIMEXHS (FY25)

Revenue

A$29.0m

Revenue growth

10%

EBITDA margin (underlying)

5.5%

Recent Developments

--

Company Snapshot

$18.7M

Revenue

300

Employees

2012

Founded

Colombia

Headquarters

SWOT Analysis

Strengths

  • High recurring revenue: About 97% of FY25 revenue recurring; ARR A$36.8m at June 2026 (1H FY26)
  • Profitability turnaround: Underlying EBITDA from -A$1.4m (FY21) to A$1.6m (FY25); 1H FY26 A$1.3m with first statutory profit (A$66,200)
  • Software margin: Software segment about 30% underlying EBITDA margin in FY25 (AGM 2026)
  • Hard-currency pricing: 69% of software revenue and 73% of software ARR in USD, AUD or EUR (Q2 FY26), versus 31% in FY22
  • Capital-light channel: 47 partners delivered 75% of software NARR in 1H FY26
  • Integrated data moat: Eight proprietary AI agents trained on RIMAB workflow data; deployed in RIMAB and Zacatecas
  • Low leverage: Debt reduced to A$0.25m (June 2026), from A$1.3m (June 2025)

Weaknesses

  • Customer concentration: One customer about 33% of external FY25 revenue; it delayed its March 2026 payment
  • Thin cash buffer: Cash A$2.0m (June 2026), down from A$3.3m (Dec 2025)
  • Receivables drag: 1H FY26 receipts A$12.6m versus revenue A$16.0m
  • Lumpy software sales: 1H FY26 software NARR of A$1.1m concentrated in one tender; management called smaller-deal conversion inconsistent
  • Declining software segment EBITDA: A$1.9m (1H FY24) to A$1.3m (1H FY25) to A$0.8m (1H FY26)
  • Repeated impairments and statutory losses: Goodwill impairments of A$1.3m (FY23) and A$1.7m (1H FY25); net losses FY23–FY25
  • Management turnover: CFO, COO and Sales leadership changed in 2026

Opportunities

  • Mexico public sector: Zacatecas: 20 sites; full run-rate from Sep 2026; 9 Mexican partners
  • Contracted backlog: A$2.3m software ARR contracted but not yet billing; A$1.2m expected to bill by end Q3 FY26
  • Radiology contract wins: Sanitas and Colsanitas add about A$2.0m ARR from Q3 FY26
  • Aquila+ migration and upsell: 569 installations eligible for migration and AI upsell
  • Third-party AI ecosystem: Gleamer integration creates a marketplace and upsell template
  • Improved Colombian sentiment: Early signs after the June 2026 election (1H FY26)
  • New markets via partners: Venezuela (Imágenes del Centro), El Salvador, Peru (Pulso Salud, Zepita)

Threats

  • Colombian payer liquidity: Explicitly cited across FY24–1H FY26 disclosures
  • Political and regulatory change in Colombian health: 2026 elections and administration transition (AGM 2026; 1H FY26)
  • FX: COP translation; FY22 ARR down 4% reported but up 8% in constant currency
  • Large-OEM competition: Bundled PACS in tenders (industry structure)
  • Equity dilution: Raises in 2019 (A$10m), 2020 (A$8.3m), 2022 (A$4.0m) and 2025 (A$2.6m); additional 7.1A capacity approved in 2026
  • AI regulatory scrutiny: No disclosed regulatory clearances for AI agents
  • Partner compliance risk: Need for the SAGRILAFT anti-money-laundering review of partners (passed, 1H FY26)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Apr 2025FY24 results and capital-raising presentation: equity raising of up to A$3.5m (A$2.5m placement including A$1m from directors, plus A$1m SPP)Balance-sheet repair; insider support
Apr 2025Advanced negotiations disclosed on a new Colombian radiology contract (about A$600,000 monthly recurring revenue)Potential major ARR addition
30 Apr 2025Q1 FY25: revenue A$7.1m (+1%), underlying EBITDA A$0.1m, ARR A$31.4m (+16%); Aquila+ live at 8 sites; wins at Clínica del Occidente and Hospital Moncaleano; Diodiagnóstico extensionSlow start; H2-weighted guidance
22 May 2025Director placement shares issued (Flynn 1,328,572; Banks 328,572 at A$0.35)Insider commitment
May 2025SPP completed (294,287 shares at A$0.35)Weak retail take-up relative to the A$1m target
29 Aug 20251H FY25: revenue A$13.7m (+4%), underlying EBITDA A$0.3m, ARR A$32.8m (+11%); A$1.7m Radiology CGU impairment; FY25 guidance A$27.5–28.2m revenue and A$1.3–1.6m underlying EBITDAFirst quantitative FY25 guidance
1H FY25Neurológico de México win (A$206,000 NARR)Mexico entry via Aquila Enterprise
2 Sep 20251H FY25 results call: cash A$2.5m, debt A$1.3m; 25 partners in 15 countries—
8 Sep 2025Directors issued shares in lieu of feesCash preservation
26 Sep 2025New radiology services contract signedShare price rose sharply from about A$0.235 over subsequent months
31 Oct / 4 Nov 2025Q3 FY25: revenue A$7.2m (+9%), underlying EBITDA A$0.6m, operating cash flow +A$1.2m, radiology ARR A$24.7m; software NARR A$417,000; some deals slipped into Q4 and Q1Inflection in earnings and cash
23 Dec 2025Cessation and quotation of securities; directors' fee sharesRoutine
29 Jan 2026Q4 FY25 Quarterly Activities Report and Appendix 4CFull-year delivery
Jan 2026Geopolitical event referenced at AGM: extradition of Venezuela's president to New YorkPossible regional market opening (Venezuela partner deployments followed)
27 Feb 2026FY25 results: revenue A$29.0m (+10%, above guidance top end); underlying EBITDA A$1.6m (top of guidance); ARR A$34.8m (+16%); cash A$3.3m; debt A$0.5m; after-tax loss A$2.9m; one customer about 33% of external revenueFinancial model validated
26 Feb 2026Appendix 4E, Annual Report 2025 and Corporate Governance Statement—
Q1 FY26Largest customer delays March payment to AprilConcentration and liquidity risk materialises
7 Apr 2026Securities quotation and cessationRoutine
28 Apr 2026Agentic AI platform for radiology launched (five agents)Product repositioning
30 Apr 2026Q1 FY26: revenue A$7.9m (+13%), ARR A$34.8m (+11%), cash A$2.5m; 14 software deals, A$427,000 NARR; wins in Colombia and Peru; partners delivered 60% of NARR; Colombian political risk flaggedSolid quarter; share price fell about 20% in following months
5 May 2026Chairman Flynn sells 2,181,418 shares off-market at A$0.41 (about A$894k)Notable insider sale
20 May 2026AGM: CEO options approved; additional placement capacity (Listing Rule 7.1A) approved; new CTO and Sales DirectorGovernance and capacity
25 May 2026Zacatecas, Mexico tender: 20 public hospitals and clinics; about US$384,000 NARR plus US$50,000 implementation fee; full run-rate from Sep 2026Largest single software win of the period
1 Jun 2026CFO change announced (Minhas out, Carrillo in, effective 1 Aug); unquoted securities noticesFinance leadership transition
Jun 2026Colombian presidential run-off; new administration transitionEarly signs of improved sentiment
6 Jul 2026Application for quotation of securitiesRoutine
27 Jul 2026Kamille Dietrich (Automic) appointed Company Secretary—
31 Jul 2026Q2 FY26 4C: operating cash inflow A$0.1m; receipts A$6.5m; debt A$0.25m; software ARR A$11.75mCash tight but positive
28 Aug 20261H FY26: revenue A$16.0m (+17%), underlying EBITDA A$1.3m, statutory profit A$66,200; FY26 guidance A$31.4–33.7m revenue and A$2.4–2.7m underlying EBITDA; Sanitas and Colsanitas contracts (about A$2.0m ARR from Q3 FY26); eight AI agentsFirst statutory profit half
2 Sep 20261H FY26 results presentation and call—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2022–FY2025): Total revenue rose from AUD 17.1 Mn in FY2022 to AUD 29 Mn in FY2025.
ImExHS Limited — Revenue by Segment (FY2022–FY2025)
Series (AUD Mn)FY2022FY2023FY2024FY2025
Total revenue17.119.726.529
Software revenue6.47.68.910
Radiology Services revenue10.712.117.619

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. IMEXHS Reports 1H FY26 Results (ASX) — 28 Aug 2026 — 1H FY26 financials, guidance, leadership, contracts, AI agents
  2. 1H FY26 Results Presentation (ASX) — 2 Sep 2026 — Segment table, strategy pillars
  3. 2026 AGM Chairman and CEO Addresses (ASX) — 20 May 2026 — Strategy, RIMAB turnaround, Aquila+
  4. IMEXHS Reports FY25 Results / Appendix 4E / Annual Report 2025 (ASX) — 26–27 Feb 2026 — FY25 figures (via company and secondary summaries)
  5. Q1 FY26 and Q2 FY26 Quarterly Activities Reports (summaries) — 30 Apr 2026; 31 Jul 2026 — Quarterly data
  6. IMEXHS Reports 1H FY25 Results (ASX) and 1H FY25 call transcript — 29 Aug and 2 Sep 2025 — 1H FY25 data, impairment, guidance
  7. Q3 FY25 call transcript — 4 Nov 2025 — Q3 FY25 data
  8. IMEXHS Reports FY24 Results: Preliminary Final Report · Annual Report 2024 · FY24 Capital Raising Presentation — 28 Feb, 31 Mar, 3 Apr 2025 — FY24 figures, hard-currency mix
  9. FY23 Results announcement and Investor Presentation; 1H FY23 and 1H FY24 Results — 2023–2024 — FY23 figures, impairment, restatements
  10. FY22 Results; 2022 Annual Report: Q1–Q4 FY22 4Cs · Investor Update Mar 2023 — 2022–2023 — FY22 figures, segment data
  11. FY21 Results and Investor Presentation: Q1–Q4 FY21 4Cs · Trading Update Dec 2021 — 2021–2022 — FY21 figures, RIMAB, Neusoft
  12. RIMAB acquisition announcement and EGM booklet — Jul and Sep 2021 — Deal terms
  13. 2018 RTO completion and name-change announcements; 2019–2020 capital-raise, chairman and consolidation announcements — 2018–2020 — Corporate history
  14. InvestSMART (Morningstar data), MarketIndex, TradingView, TipRanks, Simply Wall St, MarketScreener, Business News WA, PitchBook — 2025–2026 — Prices, market capitalisation, aggregated financials, director data (secondary)
  15. Smallcaps: StockWireX · Kalkine Media · LetsDataScience — May–Aug 2026 — FY25 and tender summaries (secondary; note US$ labelling discrepancy)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.